Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced two late-breaking presentations with results from a pooled analysis of four pivotal phase III trials of the investigational agent empagliflozin* in people with type 2 diabetes (T2D).

In the pooled analysis, presented at the American Diabetes Association 73rd Scientific Sessions®, people with T2D treated with empagliflozin versus placebo achieved significant reductions in HbA1c, fasting plasma glucose (FPG), weight and blood pressure after 24 weeks.1 In the same analysis, people treated with empagliflozin vs. placebo experienced an increased frequency of genital infections, but not urinary tract infections (UTIs).2

Empagliflozin is a member of the sodium glucose co-transporter-2 (SGLT2) inhibitor class of compounds, and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption by the kidney.

"We are primarily encouraged by the blood sugar lowering results seen in this analysis," said Christophe Arbet-Engels, PhD, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "People with type 2 diabetes face different challenges. Many of them are not meeting their blood sugar level goals and have difficulties managing other factors such as weight and increased blood pressure."

About Posters #69-LB and #74-LB
Both posters are based on pooled data from 2,477 people with T2D who participated in one of four randomized, placebo-controlled phase III trials that investigated empagl
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014  Patients in today,s changing health care ... in an outpatient setting versus a hospital. In an ... ensure that patients continue to receive high quality medical ... its new internal medicine residency program. The program,s progressive ... office, clinic and even virtual settings. ...
(Date:9/15/2014)... LAVAL, Quebec , Sept. 15, 2014  Valeant ... today announced that its wholly owned subsidiary, Valeant Pharmaceuticals ... aggregate principal amount of its 6.75% Senior Notes due ... on October 15, 2014 and has mailed an irrevocable ... September 15, 2014, a copy of the irrevocable notice ...
(Date:9/15/2014)... 15, 2014 myMatrixx has extended its contract ... with an expanded role that includes direct involvement in ... a nationally recognized physiatrist and pain management specialist, published ... and workers, compensation, is Board Certified in physical medicine ... of Pain Medicine and subspecialty boarded by the American ...
Breaking Medicine Technology:Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
... May 5, 2011 /PRNewswire-Asia/ -- People have become more and ... more services in food, clothing, housing, and transport. However, it ... and easy diagnosis. Patients have to wait long to check ... the diagnosis. For office workers, sometimes they have to spend ...
... Consumer Healthcare Products Association (CHPA), representing the makers ... announces plans to convert these pediatric products to ... place, starting in mid-2011, parents and caregivers can ... as current labeling and dosing instructions for these ...
Cached Medicine Technology:Providing More Detailed Diagnosis in Less Time 2OTC Industry Announces Voluntary Transition to One Concentration of Single-Ingredient Pediatric Liquid Acetaminophen Medicines 2
(Date:9/15/2014)... Sept. 15, 2014 (HealthDay News) -- U.S. heart experts ... electrocardiogram (ECG) when evaluating young people for underlying heart ... The American Heart Association and the American College of ... detailed personal and family medical history along with a ... or congenital (existing from birth) risks for sudden cardiac ...
(Date:9/15/2014)... September 12, 2014 - An estimated 8% of ... at some point during their lifetime. Brought on by ... the result of altered chemistry and physiology of the ... brain versus one altered by PTSD is essential to ... Center for BrainHealth at The University of Texas at ...
(Date:9/15/2014)... September 15, 2014 This year, ... founding in 2007. To mark the special occasion, Avenidas ... supporting the village and helping it to get started ... secure and fun community for seniors. Members of Avenidas ... and live in their own homes. They are able ...
(Date:9/15/2014)... Amy Norton HealthDay Reporter ... small number of medications are responsible for sending thousands of ... government study finds. Each year between 2007 and 2011, ... after getting a hold of family members, medication, according to ... "Three-quarters of those children were just 1 or 2 years ...
(Date:9/15/2014)... 15, 2014 Array Health ... technology, today announced that Independence Blue Cross ... southeastern Pennsylvania, has selected the Array Spectrum™ Private ... exchange marketplace for employers with more than 100 ... Spectrum™, Independence will offer employer groups a comprehensive ...
Breaking Medicine News(10 mins):Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:EEG study findings reveal how fear is processed in the brain 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 2Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 3
... comes to chronic disease care, study finds , , TUESDAY, ... factor driving soaring rates of chronic disease in the ... their European counterparts, a new study finds. , It,s ... such as diabetes and heart disease account for some ...
... October 1, 2007 -- According to a study conducted ... lesbian, gay, and bisexual populations, blacks and Latinos do ... on the theory that stress related to prejudice would ... black lesbians, gay men, and bisexuals face prejudice related ...
... treatments can be the worst news a cancer patient ... of Missouri-Columbia is working steadfastly to learn why some ... drug cisplatin, in hopes of identifying the particular genes ... as possible. , In a paper published in the ...
... The first significant genetic finding in premenstrual dysphoric ... a very severe form of the more commonly known ... 5-8% of women, and is associated with severe emotional ... anger, headaches, weight gain and more, to such an ...
... When an adult suffers a cardiorespiratory arrest the rapid ... avoid sudden death in many cases. Nevertheless, defibrillation also ... that passes from the moment of the attack, the ... in order to avoid avoidable deaths, more and more ...
... N.J., Oct. 2 MedQuist Inc.,(Pink Sheets: ... multi-year agreement,with MedAssets Supply Chain Systems, one ... the relationship with MedAssets and,allowing them to ... speech,recognition and clinical documentation solutions. As ...
Cached Medicine News:Health News:Obesity Driving Rising U.S. Health Costs 2Health News:Obesity Driving Rising U.S. Health Costs 3Health News:Black gay men, lesbians, have fewer mental disorders than whites, says Mailman School of PH study 2Health News:MU researchers studying model to learn why certain cancers become resistant to drugs 2Health News:First significant genetic finding in severe PMS, or PMDD 2Health News:Algorithms to reanimate the heart 2Health News:Algorithms to reanimate the heart 3Health News:MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions 2Health News:MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: